Covered recipient · General Payments record
KELLY GEORGE MCCAUL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$91,414.09
99 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,006.25 | 16 |
| Honoraria | $13,562.50 | 10 |
| Travel and Lodging | $9,173.78 | 37 |
| Food and Beverage | $1,541.56 | 34 |
| Consulting Fee | $1,130.00 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Therakos LLC | $29,831.66 | 25 |
| Incyte Corporation | $26,952.34 | 38 |
| Janssen Biotech, Inc. | $20,471.95 | 19 |
| Karyopharm Therapeutics Inc. | $13,562.50 | 10 |
| E.R. Squibb & Sons, L.L.C. | $455.00 | 1 |
| Daiichi Sankyo Inc. | $85.25 | 4 |
| Merck Sharp & Dohme LLC | $33.28 | 1 |
| Rigel Pharmaceuticals, Inc. | $22.11 | 1 |
Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KELLY GEORGE MCCAUL
NPI 1295701522 · CMS profile ID 194337
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SIOUX FALLS, SD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
99 matching records · $91,414.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 99.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Incyte Corporation | $1,370.00 | 11/19/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225971494 | CMS |
| Karyopharm Therapeutics Inc. | $1,550.00 | 11/10/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246647664 | CMS |
| Therakos LLC | $7,980.00 | 10/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219324 | CMS |
| Therakos LLC | $5,985.00 | 10/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219352 | CMS |
| Daiichi Sankyo Inc. | $26.63 | 10/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197037211 | CMS |
| Incyte Corporation | $685.00 | 10/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226141295 | CMS |
| Therakos LLC | $17.96 | 10/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219354 | CMS |
| Therakos LLC | $17.36 | 10/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219362 | CMS |
| Therakos LLC | $5.57 | 10/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219364 | CMS |
| Therakos LLC | $458.86 | 10/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219366 | CMS |
| Therakos LLC | $126.00 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219350 | CMS |
| Therakos LLC | $14.96 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219356 | CMS |
| Therakos LLC | $26.77 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219358 | CMS |
| Therakos LLC | $62.00 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219360 | CMS |
| Therakos LLC | $181.74 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219368 | CMS |
| Therakos LLC | $121.87 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219322 | CMS |
| Therakos LLC | $15.00 | 10/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219326 | CMS |
| Therakos LLC | $19.94 | 10/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219328 | CMS |
| Therakos LLC | $17.97 | 10/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219330 | CMS |
| Therakos LLC | $366.82 | 10/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219332 | CMS |
| Therakos LLC | $264.42 | 10/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219334 | CMS |
| Karyopharm Therapeutics Inc. | $1,550.00 | 09/23/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246647656 | CMS |
| Therakos LLC | $6,650.00 | 09/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219336 | CMS |
| Therakos LLC | $26.91 | 09/16/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219338 | CMS |
| Therakos LLC | $48.94 | 09/16/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219340 | CMS |
| Karyopharm Therapeutics Inc. | $387.50 | 09/12/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246647660 | CMS |
| Therakos LLC | $34.64 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219342 | CMS |
| Therakos LLC | $22.56 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219344 | CMS |
| Therakos LLC | $22.00 | 09/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219346 | CMS |
| Therakos LLC | $694.37 | 09/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219348 | CMS |
| Janssen Biotech, Inc. | $941.97 | 08/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174799107 | CMS |
| Janssen Biotech, Inc. | $4,162.50 | 08/11/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174801353 | CMS |
| Janssen Biotech, Inc. | $90.48 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174800070 | CMS |
| Janssen Biotech, Inc. | $416.25 | 08/05/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174801245 | CMS |
| Therakos LLC | $6,650.00 | 07/28/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228219320 | CMS |
| Karyopharm Therapeutics Inc. | $1,550.00 | 07/22/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246647649 | CMS |
| Daiichi Sankyo Inc. | $21.99 | 07/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197084509 | CMS |
| Janssen Biotech, Inc. | $5.50 | 07/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174799964 | CMS |
| Janssen Biotech, Inc. | $5.50 | 07/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174799116 | CMS |
| Incyte Corporation | $4,795.00 | 06/12/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226041870 | CMS |
| Daiichi Sankyo Inc. | $17.30 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197078503 | CMS |
| Incyte Corporation | $5,480.00 | 06/03/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226171311 | CMS |
| Karyopharm Therapeutics Inc. | $1,550.00 | 06/03/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246647653 | CMS |
| Janssen Biotech, Inc. | $1,130.67 | 05/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174800346 | CMS |
| Janssen Biotech, Inc. | $850.63 | 05/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174799590 | CMS |
| Janssen Biotech, Inc. | $4,162.50 | 05/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174798632 | CMS |
| E.R. Squibb & Sons, L.L.C. | $455.00 | 05/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184496152 | CMS |
| Janssen Biotech, Inc. | $124.99 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174799832 | CMS |
| Incyte Corporation | $33.52 | 05/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226041714 | CMS |
| Incyte Corporation | $54.85 | 05/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226041894 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2024 | Principal investigator | $17,061.66 | 2 |
| PY2022 | Principal investigator | $4,880.00 | 5 |
| PY2021 | Principal investigator | $12,693.30 | 2 |
| PY2020 | Principal investigator | $47,256.65 | 21 |
| PY2019 | Recipient | $935.00 | 1 |
| PY2019 | Principal investigator | $188,118.29 | 49 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
50 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Celgene Corporation | $935.00 | 12/09/2019 | Covered Recipient Physician | A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) | No dispute reported | 06/30/2026 | 675414177 |
| Principal investigator 1 | Celgene Corporation | $2,219.10 | 11/21/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) | No dispute reported | 06/30/2026 | 675414591 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $196.74 | 11/20/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161181 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $198.61 | 11/19/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161183 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 11/13/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161285 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,746.00 | 11/05/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161283 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $287.39 | 10/08/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161179 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $109.83 | 09/17/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686159599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,309.00 | 09/16/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens | No dispute reported | 06/30/2026 | 654235577 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,112.00 | 09/09/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) | No dispute reported | 06/30/2026 | 654235575 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $262.32 | 09/09/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686159597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 09/02/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens | No dispute reported | 06/30/2026 | 654235579 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $198.61 | 08/13/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686159601 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $524.64 | 08/12/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161273 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 07/29/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) | No dispute reported | 06/30/2026 | 654235573 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $94.77 | 07/16/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686159603 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $198.49 | 07/16/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686159605 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $873.00 | 07/16/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161265 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $198.49 | 07/16/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161267 |
| Principal investigator 1 | Janssen Research & Development, LLC | $366.00 | 06/25/2019 | Non-covered Recipient Entity Avera Mckennan | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant | No dispute reported | 06/30/2026 | 654243375 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 06/25/2019 | Non-covered Recipient Entity Avera Mckennan | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant | No dispute reported | 06/30/2026 | 654243377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $178.00 | 06/14/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) | No dispute reported | 06/30/2026 | 654235589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,986.00 | 06/14/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) | No dispute reported | 06/30/2026 | 654235591 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $326.07 | 05/29/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161269 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $436.50 | 05/29/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161281 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 05/23/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES | No dispute reported | 06/30/2026 | 666518193 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,619.00 | 05/07/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161271 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 05/07/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161279 |
| Principal investigator 1 | Amgen Inc. | $7,662.00 | 05/03/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | P3 Multiple Myeloma Frontline | No dispute reported | 06/30/2026 | 675779065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 04/29/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 654235583 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 04/16/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | AC220-007 | No dispute reported | 06/30/2026 | 688839395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 04/15/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens | No dispute reported | 06/30/2026 | 654235585 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $1,000.00 | 04/04/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | PCYC-1141-CA | No dispute reported | 06/30/2026 | 673107555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 04/01/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens | No dispute reported | 06/30/2026 | 654235587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 03/28/2019 | Non-covered Recipient Entity Avera Mckennan | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant | No dispute reported | 06/30/2026 | 654243373 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $436.50 | 03/26/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,802.00 | 03/18/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens | No dispute reported | 06/30/2026 | 654235593 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 03/15/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | No dispute reported | 06/30/2026 | 654235581 |
| Principal investigator 1 | Amgen Inc. | $1,048.00 | 03/06/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | P3 Multiple Myeloma Frontline | No dispute reported | 06/30/2026 | 675779063 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $196.74 | 03/04/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161277 |
| Principal investigator 1 | Celgene Corporation | $37,590.51 | 02/14/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) | No dispute reported | 06/30/2026 | 675414607 |
| Principal investigator 1 | Incyte Corporation | $887.40 | 02/05/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES | No dispute reported | 06/30/2026 | 666518151 |
| Principal investigator 1 | Celgene Corporation | $34,305.00 | 02/01/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | No dispute reported | 06/30/2026 | 675414593 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,782.22 | 01/29/2019 | Non-covered Recipient Entity AVERA MCKENNAN d b a | TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | No dispute reported | 06/30/2026 | 686161275 |
| Principal investigator 1 | Incyte Corporation | $53.70 | 01/28/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES | No dispute reported | 06/30/2026 | 666518187 |
| Principal investigator 1 | Incyte Corporation | $286.40 | 01/28/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES | No dispute reported | 06/30/2026 | 666518189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,706.25 | 01/24/2019 | Non-covered Recipient Entity Avera Mckennan | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant | No dispute reported | 06/30/2026 | 654243371 |
| Principal investigator 1 | Celgene Corporation | $14,733.46 | 01/16/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (MEDI4736-MDS-001) | No dispute reported | 06/30/2026 | 675414601 |
| Principal investigator 1 | Celgene Corporation | $443.22 | 01/07/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | No dispute reported | 06/30/2026 | 675414595 |
| Principal investigator 1 | Celgene Corporation | $38,294.33 | 01/03/2019 | Covered Recipient Teaching Hospital AVERA MCKENNAN | An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (MEDI4736-MDS-001) | No dispute reported | 06/30/2026 | 675414599 |